Review
Immunology
Anne K. Muehlig, Sydney Gies, Tobias B. Huber, Fabian Braun
Summary: This review summarizes the current knowledge on viral infections associated with collapsing glomerulopathy, with a special focus on the influence of systemic immune responses and potential mechanisms propagating its development.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Urology & Nephrology
Ying Zhu, Yun Fan, Feng Xu, Shaoshan Liang, Dandan Liang, Ping Li, Yuanyuan Xia, Xiaodong Zhu, Fan Yang, Jinsong Chen, Caihong Zeng
Summary: In this study, 60.6% of TG patients were found to have concomitant FSGS, which was associated with more severe clinicopathological features and worse allograft survival. The presence of FSGS in TG patients was independently associated with higher proteinuria, serum creatinine levels, chronic glomerulopathy score, and a higher kidney allograft loss rate.
AMERICAN JOURNAL OF NEPHROLOGY
(2021)
Article
Oncology
Samy Hakroush, Svenja Wulf, Julia Gallwas, Bjoern Tampe
Summary: Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate approved for HER2-positive breast cancer. A study reported kidney biopsy findings of collapsing FSGS after initiation of T-DM1 therapy, highlighting the importance for nephrologists to be aware of this potentially severe complication due to T-DM1 usage.
FRONTIERS IN ONCOLOGY
(2021)
Article
Urology & Nephrology
Jing Yang, Yongli Xu, Linxia Deng, Luowen Zhou, Liru Qiu, Yu Zhang, Jianhua Zhou
Summary: This study identified three cases of isolated proteinuria and FSGS caused by CUBN gene mutations, expanding the spectrum of renal manifestation and genotype of CUBN gene mutations.
Article
Biochemistry & Molecular Biology
Xu He, Lingling Yang, Meiqiu Wang, Pei Zhang, Ren Wang, Daxi Ji, Chunlin Gao, Zhengkun Xia
Summary: This study found that reduced expression of GPX4 is associated with focal segmental glomerulosclerosis (FSGS) and targeting ferroptosis could be a promising therapeutic option for FSGS patients. Treatment with the ferroptosis inhibitor Fer1 reduced proteinuria, prevented glomerulosclerosis, and attenuated podocyte injury in an FSGS mouse model.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
(2023)
Article
Chemistry, Multidisciplinary
Qiong-Dan Hu, Hong-Lian Wang, Jian Liu, Tao He, Rui-Zhi Tan, Qiong Zhang, Hong-Wei Su, Fahsai Kantawong, Hui-Yao Lan, Li Wang
Summary: Btg2 plays a pathogenic role in FSGS by promoting podocyte injury through a Smad3-dependent epithelial-mesenchymal transition pathway.
Article
Urology & Nephrology
Fang Li, Yili Fang, Qiyuan Zhuang, Meichu Cheng, Desmond Moronge, Hao Jue, Oded Meyuhas, Xiaoqiang Ding, Zhigang Zhang, Jian-Kang Chen, Huijuan Wu
Summary: The phosphorylation of ribosomal protein S6 (rpS6) plays a crucial role in podocyte hypertrophy and loss during the pathogenesis of focal segmental glomerulosclerosis (FSGS). Inhibiting rpS6 phosphorylation can effectively attenuate podocyte hypertrophy and depletion, thereby reducing the formation of FSGS lesions.
KIDNEY INTERNATIONAL
(2022)
Article
Biochemistry & Molecular Biology
Xuejing Zhu, Dan Gao, Vittorio Albertazzi, Jianyong Zhong, Li-Jun Ma, Liping Du, Yu Shyr, Valentina Kon, Hai-Chun Yang, Agnes B. Fogo
Summary: The study found that long-term treatment with high-dose angiotensin receptor blocker (ARB) and nonspecific antihypertensive therapy can ameliorate the progression of glomerulosclerosis. Among them, ARB treatment showed superior preservation of podocyte integrity, decreased proteinuria and aldosterone levels, and higher survival rate in uremic rats compared to other treatment methods.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Urology & Nephrology
Mahmoud Kallash, Yujie Wang, Abigail Smith, Howard Trachtman, Rasheed Gbadegesin, Carla Nester, Pietro Canetta, Chen Wang, Tracy E. Hunley, C. John Sperati, David Selewski, Isabelle Ayoub, Tarak Srivastava, Amy K. Mottl, Jeffrey Kopp, Brenda Gillespie, Bruce Robinson, Dhruti Chen, Julia Steinke, Katherine Twombley, Kimberly Reidy, Krzysztof Mucha, Larry A. Greenbaum, Brooke Blazius, Margaret Helmuth, Peleg Yonatan, Rulan S. Parekh, Susan Hogan, Virginie Royal, Vivette D'Agati, Aftab Chishti, Ronald Falk, Ali Gharavi, Lawrence Holzman, Jon Klein, William Smoyer, Matthias Kretzler, Debbie Gipson, Jason M. Kidd
Summary: Background: FSGS is a heterogeneous diagnosis with a guarded prognosis. APOL1 gene polymorphisms are associated with developing FSGS and faster progression to kidney failure. Understanding the natural history of FSGS patients with APOL1 risk alleles is important for patient care and intervention studies.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
(2023)
Review
Medicine, General & Internal
Erico Murilo Monteiro Cutrim, Precil Diego Miranda de Meneses Neves, Marcos Adriano Garcia Campos, Davi Campos Wanderley, Antonio Augusto Lima Teixeira-Junior, Monique Pereira Rego Muniz, Francisco Rasiah Ladchumananandasivam, Orlando Vieira Gomes, Rafael Fernandes Vanderlei Vasco, Dyego Jose de Araujo Brito, Joyce Santos Lages, Natalino Salgado-Filho, Felipe Leite Guedes, Jose Bruno de Almeida, Marcelo Magalhaes, Stanley de Almeida Araujo, Gyl Eanes Barros Silva
Summary: Collapsing glomerulopathy (CG) is a clinicopathologic entity characterized by glomerular collapse, podocyte hypertrophy and hyperplasia. It is more prevalent among populations with African descent. Risk factors include APOL1 gene mutations, HIV infection, and SARS-CoV-2 infection. CG presents with severe symptoms and worse prognosis compared to other FSGS subtypes.
FRONTIERS IN MEDICINE
(2022)
Review
Medicine, General & Internal
Mohammad A. Qamar, Lucas M. Kogut, Sameer S. Tebha, Aabiya Arif, Jesse Ninmol, Muhammad Abdul R. Razzaque, Khulud Qamar, Abubakr Yosufi
Summary: This study conducted a comprehensive review of the scientific literature from January 2020 to February 2022, focusing on collapsing glomerulopathy in patients with coronavirus disease-2019. The findings showed that respiratory system symptoms and hematuria were the most common clinical manifestations, while proteinuria and acute tubular injury were common laboratory and microscopic findings. The study also found a higher correlation between symptoms and microscopic results with collapsing glomerulopathy in the dialysis-dependent group.
ANNALS OF MEDICINE AND SURGERY
(2023)
Article
Multidisciplinary Sciences
Takaya Ozeki, Michio Nagata, Takayuki Katsuno, Koji Inagaki, Kazunori Goto, Sawako Kato, Yoshinari Yasuda, Naotake Tsuboi, Shoichi Maruyama
Summary: This study analyzed the clinical implication of unclassified segmental lesions in Japanese adult patients with nephrotic syndrome compared to Columbia-classified FSGS. The results showed that unclassified segmental lesions may have equivalent clinical impact as Columbia classification of FSGS, with similar treatment responses and no significant difference in the decline of eGFR.
Article
Medicine, Research & Experimental
Su-Wei Hu, Yuan-Hung Wang, Jhy-Shrian Huang, Yea-Mey Yang, Chia-Chang Wu, Chao-Wen Cheng
Summary: The study found that vardenafil treatment can alleviate proteinuria, renal dysfunction, and hypercholesterolemia induced by focal segmental glomerulosclerosis, and improve the histopathological damage of the kidneys.
Article
Pediatrics
George W. Burke, Jayanthi Chandar, Junichiro Sageshima, Mariella Ortigosa-Goggins, Pooja Amarapurkar, Alla Mitrofanova, Marissa J. Defreitas, Chryso P. Katsoufis, Wacharee Seeherunvong, Alexandra Centeno, Javier Pagan, Lumen A. Mendez-Castaner, Adela D. Mattiazzi, Warren L. Kupin, Giselle Guerra, Linda J. Chen, Mahmoud Morsi, Jose M. G. Figueiro, Rodrigo Vianna, Carolyn L. Abitbol, David Roth, Alessia Fornoni, Phillip Ruiz, Gaetano Ciancio, Eduardo H. Garin
Summary: Podocyte B7-1 staining in biopsies of KTRs with post-transplant FSGS identifies a subset of patients who may benefit from abatacept.
PEDIATRIC NEPHROLOGY
(2023)
Review
Cell Biology
Fabian Braun, Inka Homeyer, Nada Alachkar, Tobias B. Huber
Summary: Researchers summarized the current knowledge of immune effector cells, secreted soluble factors, and podocyte response in immune-mediated (primary) FSGS.
CELL AND TISSUE RESEARCH
(2021)